EyePoint Reports Strong Cash Position and Pivotal Phase 3 Progress for DURAVYU in Wet AMD and DME

summarizeSummary

EyePoint, Inc. announced a robust cash position of $300 million, providing a runway into Q4 2027, and reported significant progress in its Phase 3 clinical programs for DURAVYU in wet AMD and DME.

check_boxKey Events

• Strong Cash Position

  Reported approximately $300 million in cash and investments as of December 31, 2025.

• Extended Cash Runway

  Cash runway is projected into the fourth quarter of 2027, fully funding both Phase 3 DURAVYU programs.

• Wet AMD Phase 3 Progress

  Completed enrollment of over 900 patients in LUGANO and LUCIA trials, with topline data for LUGANO expected in mid-2026.

• DME Phase 3 Initiation

  First patient dosing for pivotal Phase 3 DME trials (COMO and CAPRI) is anticipated in Q1 2026.

auto_awesomeAnalysis

This 8-K filing provides a highly positive update on EyePoint's financial health and its lead product candidate, DURAVYU. The company's $300 million cash and investments ensure funding through key clinical milestones, including the anticipated mid-2026 topline data for the wet AMD program and the initiation of Phase 3 trials for DME in Q1 2026. The successful completion of enrollment for the wet AMD trials and positive safety reviews de-risk the development pathway. This comprehensive update significantly strengthens the investment thesis by confirming financial stability and advancing critical product development towards potential commercialization in multi-billion-dollar markets.